RxDoctor Payments Data

Mayur Vora, NP

Nurse Practitioner · Sacramento, CANPI 1588313381

Payments from drug & device makers

$2,377in general payments, 2019–2025

Across 46 payments — averaging $51.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$1K
  • Abbott$361
  • Bard Peripheral Vascular, Inc.$135
  • Cardiovascular Systems Inc.$92
  • Baxter Healthcare$86
  • Scpharmaceuticals Inc.$40
  • plus $277 from 12 others

What the payments were for

  • Travel & lodging$77833%
  • Food & beverage$1,59967%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,377 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$14,912
Medicare patients
83
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan36$27,996
EliquisApixaban37$27,331
FarxigaDapagliflozin Propanediol17$13,829
ClopidogrelClopidogrel Bisulfate80$1,233
Atorvastatin Calcium97$815
Eplerenone13$798
Metoprolol Succinate69$668
Amlodipine Besylate69$366
Albuterol Sulfate HfaAlbuterol Sulfate13$334
Rosuvastatin Calcium31$325
Carvedilol48$299
Pantoprazole Sodium28$271
Losartan Potassium26$241
Valsartan11$200
Metformin Hcl37$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$16$27,99636 claims
PfizerEliquis$16$27,33137 claims
AstraZenecaFarxiga$15$13,82917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →